Vnitr Lek 2020, 66(8):478-482 | DOI: 10.36290/vnl.2020.143

Contemporary state and perspectives of obesity pharmacotherapy

Štěpán Svačina
III. interní klinika - klinika endokrinologie a metabolismu 1. LF UK a VFN, Praha

The history of obesity pharmacotherapy is controversial. Many drugs are not used more due to severe side effects. Today we have four effective antiobesity drugs. The effect of some of them is comparable with bariatric sugary. Weight loss induced by bariatric surgery is culminating in the first year. The effect of incretine analogues is progressive in several years and culminating later. There are many antiobesity drugs in development. Both centrally or peripherally acting new drugs will be available soon. Even targeted therapy using antibodies will be used in obesitology soon.

Keywords: antiobesity drugs, incretine based therapy, targeted therapy.

Published: December 15, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Svačina Š. Contemporary state and perspectives of obesity pharmacotherapy. Vnitr Lek. 2020;66(8):478-482. doi: 10.36290/vnl.2020.143.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Svačina Š. Léčba obézního diabetika, Mladá Fronta, Praha, 2018.
    2. Nissen SE, et al. Effect of Naltrexone‑Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. JAMA. 2016; 315(10): 990-1004. Go to original source... Go to PubMed...
    3. Svačina Š. Obezitologie a teorie metabolického syndromu, Triton, Praha 2015.
    4. Svačina Š. Antidiabetika - historie, současnost a perspektivy. Axonite, Praha, 2016.
    5. Svačina Š. Semaglutid - zlom v léčbě obezity Acta medicinae, 2020; (1) 1: 37-39.
    6. Astrup A, et al. Effects of liraglutide in the treatment of obesity: a randomised, double‑blind, placebo‑controlled study. Lancet. 2009; 374: 1606-1616. Go to original source... Go to PubMed...
    7. Sangeeta P Bhat, Current Drug Targets in Obesity Pharmacotherapy - A Review Curr Drug Targets. 2017; 18(8): 983-993. Go to original source... Go to PubMed...
    8. Gitanjali Srivastava, Caroline Apovian 2Future Pharmacotherapy for Obesity: New Anti‑obezity Drugs on the Horizon. Curr Obes Rep 2018; 7(2): 147-161. Go to original source... Go to PubMed...
    9. Nicholas T Bello, Matthew R. Zahner Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity Tesofensin Curr Opin Investig Drugs 2009; 10(10): 1105-1116. Go to PubMed...
    10. Garito T, et al. Bimagrumab improves body composition and insulin sensitivity in insulin‑resistant individuals. Diabetes Obes Metab. 2018; 20(1): 94-102. Go to original source... Go to PubMed...
    11. Caina Li. Glutazumab, a novel long‑lasting GLP-1/anti‑GLP-1R antibody fusion protein, exerts anti‑diabetic effects through targeting dual receptor binding sites Biochem Pharmacol 2018;150: 46-53. Go to original source... Go to PubMed...
    12. Wu AL, et al. Amelioration of type 2 diabetes by antibody‑mediated activation of fibroblast growth factor receptor 1. Sci Transl Med, 2011; 3(113): 113. Go to original source... Go to PubMed...
    13. Locke AE, et al. Genetic studies of body mass index yield new insights for obesity biology Nature 2015; 518(7538): 197-206. Go to original source... Go to PubMed...
    14. Davies MJ, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018; 41(12): 2669-2701. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.